Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation - Concepedia

Concepedia

Publication | Open Access

Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation

DOI Full Paper Access

16

Citations

28

References

2017

Year

Stefania Napolitano, Giulia Martini, Erika Martinelli, Valentina Belli, Alessia Parascandolo, Mikko O. Laukkanen, Vincenzo Sforza, Floriana Morgillo, Davide Ciardiello, Fortunato Ciardiello,

Abstract

These results suggest that the treatment with SYM004 could be a strategy to overcome acquired resistance to first generation of anti-EGFR therapies in mCRC as a result of MET activation.

References

	Year	Citations

Page 1